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1 ABSTRACT 
This work provides an elaborate characterization of human intestinal fluids (HIF) collected in fasted 
and fed state conditions. HIF from 20 healthy volunteers (10 M/F) were aspirated by intubation near 
the ligament of Treitz in a time-dependent manner (10 minute intervals) and characterized for pH, bile 
salts, phospholipids, cholesterol, triacylglycerides (TAG), diacylglycerides (DAG), 
monoacylglycerdes (MAG), free fatty acids (FFA), pancreatic lipase, phospholipase A2, and non-
specific esterase activity. For almost all parameters, a food induced effect was observed. Results were 
characterized by a high variability, as illustrated by the broad ranges observed for each parameter: pH 
(fasted: 3.4-8.3; fed 4.7-7.1), bile salts (fasted: 0.03-36.18 mM; fed 0.74-86.14 mM), phospholipids 
(fasted: 0.01-6.33 mM; fed 0.16-14.39 mM), cholesterol (fasted: 0-0.48 mM; fed 0-3.29 mM), TAG 
(fed 0-6.76 mg/ml), DAG (fed 0-3.64 mg/ml), MAG (fasted: 0-1.09 mg/ml; fed 0-11.36 mg/ml), FFA 
(fasted: 0-3.86 mg/ml; fed 0.53-15.0 mg/ml), pancreatic lipase (fasted: 26-86 µg/ml; fed 146-415 
µg/ml), phospholipase A2 (fasted: 3-6 ng/ml; fed 4.3-27.7 ng/ml), and non-specific esterase activity 
(fasted: 270-4900 U/ml; fed 430-4655 U/ml). This comprehensive overview may serve as reference 
data for PBPK modeling and the optimization of biorelevant simulated intestinal fluids for the use in 
in-vitro dissolution, solubility and permeability profiling.  
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3 INTRODUCTION 
Variability in human drug bioavailability is often attributed to variations in hepatic first-pass 
extraction 
1
, body distribution, and kidney excretion. For those orally administered drugs, variability 
may be further increased by gastrointestinal factors 
1
, including interdigestive and postprandial 
gastrointestinal motility, gastric emptying 
2
, and human intestinal fluid (HIF) composition 
3
. HIF 
composition is especially important for its effect on the dissolution and permeation of lipophilic drugs 
with a limited aqueous solubility, i.e. BCS (biopharmaceutics classification system) class II and IV 
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compounds 
4
. Predicting the oral absorption potential of this type of drugs requires in vitro tools for 
dissolution, solubility and permeability, and physiologically-based pharmacokinetic (PBPK) 
simulation models that account for HIF composition and its related variability.  
The importance of bile salts, pH, phospholipids, lipid degradation products, cholesterol, and enzymatic 
secretions for absorption is generally accepted. The pH is known to affect drug ionization behavior 
5,6
. 
The surfactant properties of bile salts 
7
 and phospholipids 
8,9
 contribute to the solubilization of 
lipophilic compounds. After intake and enzymatic digestion of a meal, lipolytic hydrolysis products 
[triacylglycerides (TAG), diacylglycerides (DAG), monoacylglycerides (MAG), and free fatty acids 
(FFA)] form colloidal structures and are a part of mixed micelles, which impact the 
solubility/permeability of lipophilic compounds
10-12
. Cholesterol improves bilayer stability 
13
 and is 
incorporated in mixed micelles 
14
; more recently, cholesterol has been shown to affect solubility of 
several BCS II class drugs 
15
. 
As HIF is comprised of several constituents, it is prone to a large variability. In addition to inter-
subject differences, day-to-day fluctuations may also lead to intra-subject variability. Moreover, the 
dynamic nature of the intraluminal environment, for instance mediated by meal intake and 
biliary/pancreatic secretions, further enhances complexity. The pronounced variability obviously 
complicates the definition of simulated intestinal fluids (SIF) 
3
. Additionally, several limitations of the 
currently available literature data on HIF composition hinder a clear consensus on the simulation of 
HIF composition and its related variability. Data is scattered throughout numerous publications 
3,16-21
, 
all focusing on different factors and utilizing different sampling protocols. Fasted and fed state 
conditions are often collected on separate test days, making it impossible to discriminate between the 
net effect of food and the intrinsic day-to-day variability in human volunteers. Moreover, the time-
dependent evolution in HIF composition is usually neglected by using only pooled samples.  
This study aims to provide a comprehensive and relevant characterization of the composition of 
duodenal fluids and its variability. Therefore, pH, individual bile salts, phospholipids, cholesterol, 
lipid degradation products (TAG, DAG, MAG, and FFA), and enzymatic secretions (pancreatic lipase, 
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phospholipase A2, and nonspecific esterase) were analyzed in consecutively collected fasted and fed 
state, time-dependent aspirates from 20 healthy volunteers. To judge the use of pooled aspirates as 
representative samples, volunteer pools were also created and analyzed. The data enabled insight into 
inter-subject and time-dependent intra-subject variability and may contribute to the use of pooled HIF 
samples and their derived SIF composition for physiologically-based absorption profiling. 
4 MATERIALS & METHODS 
4.1 MATERIALS 
Taurochenodeoxycholic acid (TCDC), taurodeoxycholic acid (TDC), glycoursodeoxycholic acid 
(GUDC), glycochenodeoxycholic acid (GCDC), glycodeoxycholic acid (GDC), glycocholic acid 
(GC), chenodeoxycholic acid (CDC), deoxycholic acid (DC), lithocholic acid (LC), and cholic acid 
(C) were purchased from Sigma-Aldrich (St. Louis, MO).  Tauroursodeoxycholic acid (TUDC), 
ursodeoxycholic acid (UDC), and taurocholic acid were acquired from Calbiochem (Darmstadt, 
Germany). Deuterated cholic acid (Cholic-2,2,4,4-d4) was purchased from CDN isotopes (Quebec, 
Canada)  
NaCl, glacial acetic acid, chloroform, methanol, hexane, and pyridine were obtained from Merck 
(Darmstadt, Germany). The silylating agent bis(trimethylsilyl)trifluoroacetomide (BSTFA) was 
obtained from Pierce (Rockford, IL). The lipids DL-α-stearin, DL-1,2-dipalmitin, glyceryltripalmitin, 
and palmitic acid as well as the general lipase inhibitor Orlistat were obtained from Sigma-Aldrich. 
Water was purified with a Maxima system (Elga Ltd, High Wycombe Bucks, UK). Since solid meals 
are incompatible with the aspiration of intestinal fluids (clogging of catheter), the liquid meal Ensure 
Plus (Abbott Laboratories B.V., Zwolle, The Netherlands) was used to simulate a standard meal. One 
portion of 200 mL has an energy content of 300 kcal of which lipids, carbohydrates and proteins 
constitute 29%, 54%, and 17%, respectively 
4.2 SAMPLING OF HIF 
The sampling of the intestinal fluids was performed at the University Hospitals Leuven and was 
approved by the Committee of Medical Ethics (ML7918). Twenty healthy Caucasian volunteers were 
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enrolled in the study after giving written informed consent. The volunteers were selected as in a 
typical bioavailability/bioequivalence study. Ten men and ten women, aged between 18 and 31 years 
and with a BMI between 19 and 25 kg/m
2
, participated in the study. None of the volunteers had a 
history of gastrointestinal diseases and medication was omitted for 2 days before participation in the 
study. After an overnight fast, one double-lumen catheter (Salem Sump Tube 14 Ch, external diameter 
4.7 mm, Sherwood Medical, Petit Rechain, Belgium) was introduced in the duodenum (D2–D3) via 
the nose or mouth and the position was checked fluoroscopically (Figure 1A). This double-lumen 
catheter enabled the collection of intestinal fluids by means of a syringe without creating 
underpressure in the gastrointestinal (GI) tract.  
After an overnight fast of at least 12 hours (no food and only water), the volunteers were given 250 ml 
of water before initiating the sampling of fasted state intestinal fluids. Following the fasted state, 400 
mL of Ensure Plus was ingested to simulate a standard meal; this condition is referred to as the fed 
state. A glass of 250ml water was consumed 20 minutes after intake of the liquid meal (Figure 1B). 
After the ingestion of water (both for fasted and fed state), intestinal fluids were sampled every 10 min 
for a period of 90 min. In total, 18 time-dependent samples were obtained per healthy volunteer; 
sample volumes did not exceed 10ml per time-point. Intestinal samples were collected in test tubes 
containing the lipase inhibitor Orlistat dissolved in ethanol to arrest further lipolysis in vitro. A stock 
solution of 1 mM Orlistat in ethanol was used to bring the final concentration of Orlistat in the 
duodenal sample to 1 µM. This protocol allowed minor dilution of the collected samples as well as 
negligible addition of ethanol (0.1%, v/v). The applied concentration of this lipase inhibitor is 100-fold 
the IC50 (11 nM), as determined previously (Unilever R&D, Vlaardingen, data not published).  
4.3 HANDLING OF SAMPLES  
All aspirated fluids were kept on ice in closed test tubes till the end of sampling, followed by a 15-min 
centrifugation at 1500 x g and 4 °C. All samples were stored at -20 °C until further analysis. Aliquots 
(<1ml) of each sample were stored for characterization. The remainder of the collected fractions was 
pooled for each volunteer in fasted and fed state (further referred to as volunteer pools). Pools were 
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created immediately after the collection was complete. For a selected set of samples, separate aliquots 
without Orlistat were collected in order to measure esterase activity; additionally, protease inhibitors 
were added to aliquots of another set of samples used for lipase quantification. 
4.4 ANALYSIS OF SAMPLES  
4.4.1 pH 
The pH of all samples (see Sampling of HIF Section) was measured immediately upon collection 
(Hamilton Slimtrode); the pH of the volunteer pools was measured immediately after pooling. 
4.4.2 PHOSPHOLIPIDS  
Total phospholipid levels were determined enzymatically employing the Phospholipids FS kit from 
DiaSys (Holzheim, Germany). After release by phospholipase D, choline is oxidized by choline 
oxidase, which generates hydrogen peroxide. Subsequently, peroxidase forms a quinone that was 
analyzed spectrophotometrically at 570 nm 
22 
using a Tecan Infinite M200 plate reader (Tecan Group 
Ltd., Männedorf, Austria). The assay was used in a 96-well format with a detection limit of 0.1 mM.  
Biologically relevant bile salts (TC, TCDC, TDC, GC, GCDC, and GDC) at concentrations of 10 mM 
each (and combined 60 mM) did not interfere with the assay.  
4.4.3 CHOLESTEROL 
Total cholesterol was determined enzymatically employing an Amplex® Red cholesterol assay kit 
from Molecular Probes Invitrogen (Eugene, Oregon, United States). Cholesterol esters are hydrolyzed 
to free cholesterol by cholesterol esterase. Subsequently, cholesterol is oxidized by cholesterol oxidase 
to yield hydrogen peroxide. In the final step, hydrogen peroxide reacts with Horse radish peroxidase 
and Amplex® Red to form resofurin 
23
. This reaction product was measured using fluorescence (Tecan 
Infinite M200 plate reader) with an excitation/emission at 560 nm/590 nm, respectively. The detection 
limit of the assay was 200 nM. 
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4.4.4 BILE SALTS 
Bile salts were analyzed using a Thermo Fisher Scientific LC-MS/MS system. This system consisted 
of a TSQ Quantum Access™ triple quadrupole mass analyzer, equipped with an electrospray 
ionization (ESI) source, and coupled to an Accela™ U-HPLC system (San Jose, CA, USA). Data 
acquisition and peak integration were performed with the Xcalibur® 2.0.7 and LCquan® 2.5.6 
software packages, respectively. For separation, a Kinetex C18 column (1.7 μm, 100 A, 50 × 3 mm) 
with an in-line KrudKatcher ultra HPLC filter (PhenomenexR, the Netherlands) was used and the 
column temperature was kept at 30 °C. The injection volume was 25 μl using a full loop. The flow rate 
was 450 μl/min and bile salts were eluted using a gradient shown in Table 1A, with the buffer 
consisting of 5 mM ammonium acetate (pH adjusted to 3.5 with acetic acid). Samples were diluted 
1000-10000 times in 50/50 MeOH/H2O containing 200 nM deuterated cholic acid (D4C) as internal 
standard. Analysis was performed using the negative electrospray ionization mode in combination 
with the following parameters: capillary temperature 275 °C, vaporizer temperature 300 °C, sheath gas 
(N2) pressure 40 (arbitrary units), auxiliary gas (N2) pressure 45 (arbitrary units), ion sweep pressure 
20 (arbitrary units), spray voltage 3500 V, and collision gas (Ar) 1.5 mTorr. The parent and daughter 
mass of each bile salt are shown in Table 1B. Three groups of bile salts have identical mass and 
daughter ions but could be separated via HPLC. Furthermore, UDC, CDC, DC, and LC could not be 
fragmented and, therefore, the parent mass was analyzed. Total bile salt concentrations were 
determined as the sum of individual bile salts. The calibration curve was made in 50/50 MeOH/H2O 
(200 nM D4C) and was linear between 0.009 µM and 5 µM.  
The method validation showed an inter-day repeatability in a HIF standard sample (randomly selected) 
of <10.5% RSD (relative standard deviation) for the individually determined bile salts; the inter-day 
RSD for the total bile salt concentration was 5.4%. Samples containing 500 nM or 50 nM (in MeOH) 
of each individual bile salt showed a RSD of <7.9% or < 11%, respectively. The concentration 
determined in the HIF standard (stored at -20°C) remained stable for > 12months.  The intra-day RSD 
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for individual and total bile salt concentrations in the HIF standard was <8.8%, and 3.6%, respectively.  
Samples containing 500 nM or 50 nM displayed an intra-day RSD of <6.0% and <10.7%, respectively. 
During each analysis, 4 quality control (QC) samples (50nM, 500nM, 2000nM, and a HIF standard) 
were determined at least 5 times spread over the analysis (1 set of controls every 15-25 samples). All 
QC samples displayed accuracy between 90-110% and RSD <10%, for each individual bile salt.  
4.4.5 LIPID CONTENT 
After freeze-drying of a 100µl HIF sample, lipids were extracted consistent with the method of 
Armand et al.
24
 Briefly, the freeze dried samples were dissolved in 0.15 M NaCl containing 2% glacial 
acetic acid. Chloroform/methanol (2:1, v/v) was used as extraction solvent. The lower chloroform 
layer was evaporated to dryness under a stream of nitrogen. The residue was silylated using BSTFA 
(20% in pyridine, v/v). After 30 min at 60°C, the sample was dissolved in hexane and analyzed by GC 
[Fisons MFC800] with flame ionization detection according to the technique described by Duchateau 
et al.
25
 The column used was a Chrompack, CP-Sil5CB-MS column with a deactivated fused silica 
precolumn. Samples were injected ‘‘cold-on-column’’ and were heated to 360°C with a rate of 
10°C/min. Hydrogen was used as carrier gas. The injection volume was 1 μl and total run time was 50 
min. Lipids were separated according to carbon number (CN). For our purpose, peaks were integrated 
individually and combined to obtain one AUC (area under the curve) value for each class of neutral 
lipids. Peaks in the range of CN 8–18, CN 20–28, CN 30–42, and >CN 44 were assigned to  free fatty 
acids (FFA), monoacylglycerides (MAG), diacylglycerides (DAG), and triacylglycerides (TAG), 
respectively (using calibration standards of the respective classes). These integration ranges were 
chosen to minimize overlap between the different lipid classes. The amount of each class was 
calculated using the respective calibration curve: palmitic acid, mono-palmitin, di-palmitin, and 
tripalmitin standards were dissolved in hexane and appropriate volumes were evaporated under 
nitrogen to obtain known amounts of the respective standards. The standards were extracted and 
silylated identically to the unknown samples. 
4.4.6 SPECIFIC ESTERASES: PANCREATIC LIPASE & PHOSPHOLIPASE A2 
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Both pancreatic lipase and phospholipase A2 quantities were determined using a commercially 
available competitive ELISA from Bluegene (Shanghai, China). Separate aliquots were stored at -
20°C and only thawed a maximum of 2 times. Samples were diluted in PBS (pH7.4) containing 5% 
(v/v) protease inhibitor cocktail including AEBSF at 104 mM, aprotinin at 80 μM, bestatin at 4 mM, 
E-64 at 1.4 mM, leupeptin at 2 mM and pepstatin A at 1.5 mM.   
4.4.7 NON-SPECIFIC ESTERASE ACTIVTIY 
Esterase activity was assayed by measuring the conversion of p-nitrophenyl acetate to p-nitrophenyl 
which could be analyzed spectrophotometrically at 410 nm 
26 
(Tecan Infinite M200 plate reader). 
Stock solutions of both of p-nitrophenyl acetate and p-nitrophenyl were prepared in CH2Cl2 at 
concentrations between 100 and 250 mM. Enzymatic activity was measured in 20 mM Tris–HCl (pH 
8.0), 150 mM NaCl, and 0.01% Gum Arabic at 25 °C for 30 minutes. HIF samples of 5 µL were 
incubated with 0.2 mL substrate solution in 96-well clear microtiter plates. Substrate was added to the 
reaction buffer at a final concentration of 0.5 mM. Unit (U) definition: One unit will hydrolyze 1.0 
μmole of p-nitrophenyl-acetate to p-nitrophenyl per minute at pH 8.0 at 25 °C. For this assay, aliquots 
of 500 µL HIF were separated before addition of Orlistat to avoid inhibition of esterases. These 
separate aliquots were generated for 10 volunteer pools and for time-dependent samples of 3 
volunteers.  
 
5. RESULTS & DISCUSSION 
In this study, human intestinal fluids were collected as a function of time from 20 volunteers in fasted 
and fed state conditions. All HIF aspirates were characterized for pH, bile salts, phospholipids, 
cholesterol, and lipid hydrolysis products, all of which may directly affect drug solubility and/or 
permeability. Additionally, enzymes were assessed that may indirectly affect drug absorption: 
secretion of pancreatic lipase and phospholipase A2 influences the intraluminal environment through 
lipid and phospholipid degradation; esterase activity plays an important role in the conversion of ester 
prodrugs. Data are presented both as individual data points and in a time-dependent way. 
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5.1 INDIVIDUAL DATA POINTS  
In each volunteer, HIF aspirates were characterized at, on average, 17 out of a possible 18 time points, 
resulting in a total of 161 and 175 individual data points for fasted human intestinal fluids (FaHIF) and 
fed human intestinal fluid (FeHIF), respectively. These individual data points are presented in Figure 2 
providing insight into the overall duodenal variability in pH, bile salts, phospholipids, cholesterol, and 
lipid degradation products. This overview clearly shows that some factors are asymmetrically 
distributed, with mean values surpassing the more appropriate median values. It should be noted that 
such a distribution complicates the comparison of results with literature as most literature data is based 
on pooled values and/or average time profiles. 
5.1.1 pH 
In the fasted state, highly variable pH values were observed, ranging from 3.4 to 8.3 (Figure 2A). The 
mean value amounted to 6.78 and the median value to 6.88. These values are slightly higher than the 
pH defined for FaSSIF (pH 6.5), but still comparable to literature values (between pH of 6-7 
3,18
). pH 
displays a symmetrical distribution; for the majority of the samples, a pH between 6.5 and 7.5 was 
observed. However, pH values below 6.0 or above 7.5 were not unusual. In fed state conditions, a 
more narrow symmetrical distribution in pH values was observed (between 4.7 and 7.1). The observed 
mean (6.22) and median (6.28) pH values correspond closely to the median of pH 6.3 reported in 
literature 
3
. These values are higher than the pH of FeSSIF (5.0) or FeSSIF-v2 (pH 5.8). The reduced 
variability in fed state conditions might be caused by the buffer capacity of food. Ensure Plus has a pH 
of 6.6 and buffer capacity 20-24 mmol/L/ΔpH 27. 
5.1.2 BILE SALTS 
As illustrated in Figure 2B, bile salt concentrations are characterized by a large variability and an 
asymmetric distribution. Total fasted state bile salt concentrations range from 0.03 mM to 36.18 mM. 
The majority of values are clustered below 5 mM. Due to some extreme bile salt concentrations, the 
mean total concentration (4.61 mM) exceeds the median value (3.30 mM). Both mean and median are 
within the reported average range of 1.4-8.1 mM 
3,18
; the median value observed in this study is similar 
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to the median value of 3.25 mM reported by Bergstrom et.al 
3
 and corresponds to the concentration of 
sodium taurocholate used in FaSSIF (3 mM).  The range observed for fed state conditions was even 
larger, with values ranging from 0.74 to 86.14 mM.  A sizable difference was observed between the 
mean (12.65 mM) and median (9.59 mM) concentration. Both values are within the wide range of 
average values reported in literature (between 3.6-24.0 mM) 
3
; the median concentration of 11.8 mM 
reported by Bergstrom et.al is in between the observed mean and median. The observed median 
concentration is well reflected in FeSSIF-V2 (10 mM), whereas for standard FeSSIF, a higher 
concentration of bile salts (15 mM) is used.  
Variability was not only observed for total bile salt concentrations, but was also reflected in the 
composition of the individual bile salts between volunteers, as shown in Figure 3A. Each symbol in 
Figure 3A represents the average of all time-points for a single volunteer. Interestingly, the relative 
abundance of individual bile salts remained nearly constant over time for all 20 healthy volunteers 
(illustrated for 4 volunteers in Figure 3B), and no differences could be observed between fasted and 
fed state. The observed composition is largely in agreement with other studies 
18,21,28
. When 
considering conjugated bile salts, glyco-conjugated bile salts (70%) appeared to be more abundant 
than tauro-conjugated bile salts (30%); others have reported higher percentages of tauro-conjugates in 
HIF collected from the duodenum 
3,20
, which might be explained by population differences as we also 
observed a higher abundance of tauro-conjugates in a few volunteers.   
5.1.3 PHOSPHOLIPIDS 
In fasted state conditions, phospholipids display a similar asymmetric distribution as bile salts with 
values ranging from 0.01 mM to 6.33 mM (Figure 2C). Because of extremes, the mean value (0.95 
mM) exceeds the median (0.58 mM). In literature, a wide range of FaHIF phospholipid concentrations 
have been reported (0.1-1.8 mM 
18
); both mean and median values are well within this range. The 
concentration used in FaSSIF (0.75 mM) is in-between mean and median. The variability observed in 
this study may also explain why some studies report low mean concentrations (0.1-0.5 mM 
18,29
) while 
others report higher values 
30,31
. However, the clustering between 0.1 and 0.5 mM observed in this 
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study supports the lower values reported most frequently in literature 
3,18
; this lower value has also 
been adapted into FaSSIF-v2 (0.2 mM). In contrast, phospholipid concentrations measured in FeHIF 
displayed a more symmetrical distribution which results in nearly identical values for mean (4.17 mM) 
and median (4.05 mM).  Still, phospholipid concentrations in fed state conditions ranged from 0.16 
mM to 14.39 mM. These average values are better reflected in FeSSIF (3.75 mM) than in FeSSIF-v2 
(2mM). In literature, average postprandial phospholipid concentrations are reported between 1.2 and 
6.0 mM with a median of 2.15 mM 
3
; however, this study confirms a tendency towards higher values 
reported around 4 mM 
3
.  
5.1.4 CHOLESTEROL 
In FaHIF, cholesterol is only present at low concentrations ranging between 0.00 mM and 0.48 mM 
(Figure 2D). As such, there is little difference between mean (0.07 mM) and median (0.08 mM). These 
values are equal to the 0.08 mM reported by Persson et al 
28
; others have reported average fasted state 
cholesterol concentrations between 0.17 and 0.23 mM 
31,32
. A higher concentration of cholesterol in 
FaHIF (1.8 mM) was reported by Heikkila et al; that study also noted there was no difference with 
cholesterol concentrations in FeHIF (2.0 mM). In the present study, however, both cholesterol 
concentrations and variability clearly increased after intake of the liquid meal, with an observed range 
from 0.00 mM to 3.29 mM. The presence of high extremes resulted in a mean (0.71 mM) that 
moderately exceeds the median (0.57 mM). In literature, data about postprandial cholesterol 
concentrations are limited. However, the average of 0.9 mM reported by Vertzoni et al  
33
 is close to 
our observations. It should be noted that the cholesterol content in Ensure plus amounted to 0.45 mM. 
Taking into account the dilution by water intake (250ml), chyme, and intestinal secretions, it may 
suggest that endogenous secretion of cholesterol via bile increases considerably in fed state conditions.  
5.1.5 LIPIDS 
In FaHIF, the only lipid classes observed are FFA and MAG (Figure 2E), with the majority being FFA 
C16/C18; hydrolysis of phospholipids may be the source of FFA in fasted state as they mainly consist 
of C16/C18 chain lengths. Fasted state FFA concentration displayed a symmetrical distribution with 
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the bulk of values between 0 and 1 mg/ml; only a few outliers were observed resulting in an absolute 
range from 0 - 3.86 mg/ml. Consequently, mean (0.53 mg/ml, ≈2.07 mM) and median (0.45 mg/ml, 
≈1.75 mM) FFA concentrations are nearly equal and consistent with reported literature values between 
0.4 and 0.6 mg/ml 
24,30
. If present, MAG concentrations in FaHIF were generally very low. Values 
ranged between 0 mg/ml and 1.09 mg/ml (≈3.30 mM); however, only one sample exceeded 0.43 
mg/ml (1.30 mM). The mean (0.13 mg/ml, ≈0.39 mM) and median (0.10 mg/ml, ≈0.30 mM) MAG 
concentrations in FaHIF are nearly identical. In literature, the only reported MAG concentrations 
amount, on average, to 0.20 mg/ml 
30
.  
Postprandial lipid concentrations are obviously mainly determined by meal intake. The Ensure plus 
lipid content was determined to be 53 mg/ml (49 mg/ml according to manufactures specification), of 
which 92% consisted of TAG. In line with literature data 
3,21,24,30
, the majority of lipids in fed state 
duodenal fluids are degradation products in the form of FFA and MAG. The largest fraction in FeHIF 
was, by far, FFA C18. Obviously, the chain length distribution will depend on the type of food, and 
thus on the TAG present. For both FFA and MAG concentrations, a rather broad distribution was 
observed: FFA displayed a range between 0.53 and 15.0 mg/ml (≈2.1-58.7 mM), while MAG ranged 
between 0 and 11.36 mg/ml (≈0-34.4 mM). FFAs are by far the largest factor in FeHIF with a mean 
and median of 6.49 mg/ml (≈25.4 mM) and 5.63 mg/ml (≈22.0 mM), respectively. These values are 
lower than reported average FFA concentrations of 39.4 and 52.0 mM 
19,33
. The observed mean (3.05 
mg/ml, ≈9.24 mM) and median (2.75 mg/ml, ≈8.33 mM) MAG concentrations in FaHIF are in-line 
with MAG concentrations reported in literature (between 5.9 and 8.1 mM).  In all postprandial 
aspirates, advanced lipid degradation was seen, resulting in relatively low DAG and TAG 
concentrations. Fed state DAG and TAG concentrations were absent in a large amount of aspirates 
causing an asymmetrical distribution between 0.00 and 3.64 mg/ml, and between 0.00 and 6.76 mg/ml, 
respectively. Consequently, a substantial difference was observed between mean (0.61 mg/ml, ≈1.04 
mM) and median (0.36 mg/ml, ≈0.61 mM) DAG concentrations, as well as between mean (0.81 
mg/ml, ≈0.96 mM) and median (0.59 mg/ml, ≈0.70 mM) TAG concentrations.  
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5.2 TIME-DEPENDENT EVOLUTION 
The results so far illustrate that the intestine is a highly variable environment, which will definitely 
impact drug and formulation behavior. As part of this overall variability, several parameters fluctuate 
as a function of time, as demonstrated in Figure 4 which displays average values for the 20 healthy 
volunteers. Especially after intake of the meal (at 100 min), a clear time-dependent evolution is seen 
for pH, bile salts, phospholipids, cholesterol and lipid degradation products (food effect). For none of 
these factors, fasted state conditions were restored after 90 minutes of sampling in the fed state. 
In the fasted state, slightly lower pH values were observed during the first 40 min, which may be 
attributed to the initially fast transfer of (acidic) gastric contents upon intake of a glass of water 
(Figure 4A). On average, pH fluctuates around 6.5, being slightly higher in FaHIF as compared to 
FeHIF. Typically, pH varies more in the fasted state (larger SEM) than in the fed state, which was 
already demonstrated in Figure 2. Average concentrations of bile salts (Figure 4B) and phospholipids 
(Figure 4C) appear to be relatively stable in the fasted state. Postprandial concentrations increase and 
are characterized by higher variability. This variability may be attributed to the fact that the release of 
bile is not continuous, but rather pulsatile. Differences in timing and intensity of these contractions 
result in strong fluctuations as a function of time and, in some individuals, extreme values (for 
instance bile salt concentrations up to 86 mM). It is worth mentioning that the ratio of bile salt 
concentrations over phospholipid concentrations (Figure 4D) remained impressively constant in fed 
state conditions. This contrasts with this ratio observed in fasted state conditions. Cholesterol (Figure 
4E) enters the duodenum through food intake but especially through bile secretions, thus resulting in a 
similar profile as observed for bile salts and phospholipids.  
As expected, little variation was observed in the basal levels of lipid products in fasted state conditions 
(Figure 4F). Postprandially, FFA and DAG but not TAG and DAG significantly increase (as already 
demonstrated in Figure 2). The majority of lipid species are FFA, which implies a very rapid and 
effective conversion of TAG into FFA and MAG. It is also interesting to see that total duodenal lipid 
concentrations appear to be tightly controlled by gastric emptying, as they rarely exceed 15 mg/ml, in 
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agreement with the caloric-dependent gastric release 
34
. This also corresponds with a previous study by 
Clarysse et al.
30
 in which both Ensure Plus and a fat-enriched meal were administered; the higher lipid 
content in the fat-enriched meal did not result in higher duodenal lipid concentrations as a 
consequence of this caloric brake 
34,35
.  
Finally, it should be noted that food effects on HIF composition will strongly depend on the type and 
composition of the administered meal. For instance, as compared to the liquid meal used in the present 
study, solid meals will have a different effect on gastric motility and emptying, most likely resulting in 
a different time-dependency of the food effect.  
5.3 VOLUNTEER POOLS          
In view of the limited volume collected during sampling of HIF, aspirates from different volunteers 
are usually combined when using HIF for dissolution, solubility, or permeability studies. In the present 
study, no general ‘population’ pool was generated. However, volunteer pools were created by 
combining aliquots of the time-dependent aspirates per volunteer. For each volunteer, a fasted and fed 
state pool were made, each representing the average HIF aspirated during the respective 90 min time 
periods. In Figure 5, the composition of all volunteer pools is represented, demonstrating high inter-
subject variability for most factors. Despite an unequal distribution, the pool-derived means (Figure 5) 
correspond in general to the mean values obtained from all individual data points (Figure 2).  The data 
presented in Figure 5 illustrate that food effects may significantly vary between volunteers: for bile 
salt concentrations, for instance, food intake resulted in a 20-fold increase in some volunteers (e.g. HV 
6 ), while for others almost no increase (e.g. HV 5 ), or even a decrease (e.g. HV 18 ), was observed.  
Considering the high variability observed among the different volunteer pools, it is clear that 
population pools created from different volunteers can only be useful to evaluate the average effect of 
HIF on dissolution, solubility and permeation. The use of volunteer pools is critical to explore inter-
subject differences in drug and formulation performance. 
5.4 ENZYME SECRETIONS 
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The parameters discussed so far all have a direct effect on the solubilizing capacity of HIF; however, 
indirect factors that shape the intestinal environment (e.g. lipases) may pose an additional source of 
variability in absorption. In addition, intestinal esterases may hydrolyze orally dosed ester prodrugs, 
which can lead to variations in pharmacokinetic and pharmacodynamic responses to these compounds. 
As shown in Figure 6 (A-C), HIF from 10 individual volunteers (pooled samples) were studied for 
pancreatic lipase, phospholipase A2 and esterase. For 3 volunteers, time profiles were included (Figure 
6 D-F).  
5.4.1 PANCREATIC LIPASE  
Gastric (5–40%) and pancreatic lipase (40-70%) mediate the degradation of lipids and may, as such, 
exert an important indirect effect on intestinal drug absorption 
16
. As indicated in Figure 6, fasted state 
pancreatic lipase concentrations ranged between 23 and 86 µg/ml (mean = 49 ± 21 µg/ml). Pancreatic 
lipase is reported to have a specific activity of 8000 IU/mg 
16
, which means that fasted state HIF has an 
activity between ≈184 and 690 IU/ml. Postprandially, pancreatic lipase concentration increased 5-10 
fold, which is comperable to a 5-fold increase reported by Keller et. al 
36
. The observed range from 
146 µg/ml (≈1170 IU/ml) to 415 µg/ml (≈3320 IU/ml), with an average of 293 ± 93 µg/ml (≈2350 
IU/ml), was in line with reported values between 600-7000 IU 
16
. The lack of DAG and TAG at all 
time-points indicates a potent degradation of TAG by lipases present in the GI tract.  Figure 6-D 
illustrates that, postprandially, pancreatic lipase is secreted in a similar manner (contraction-wise) as 
other secretions from the papilla of Vater (e.g. bile salts and phospholipids). 
5.4.2 PHOSPHOLIPASE A2 
Phospholipids and lyso-phospholipids each have distinct properties with respect to absorption because 
lyso-phospholipids are stronger surfactants 
9,37,38
. Phospholipase A2 mediates the conversion to the 
lyso form. Several studies have shown that nearly 90% of phospholipids present in duodenal fluids are 
lyso-phospholipids 
21,28
. Despite their reported effect on the absorption of vitamin A/E and cholesterol 
14,37
, little is known about duodenal phospholipase A2 (PLA2) concentrations (only using secretin 
stimulation 
39
). In fasted state, PLA2 concentrations ranged between 3 and 6 ng/ml (mean = 4.3 ± 1 
17 
 
ng/ml), which increased approximately 5-fold in fed state conditions with an observed range between 
4.3 ng/ml and 27.7 ng/ml (mean = 14.1 ± 7.8 ng/ml). Figure 6-E illustrates that PLA2 concentrations 
increase, on average, in a similar proportion and contraction-like manner as phospholipid 
concentrations in Figure 4C (4-5 fold).  
5.4.3 ESTERASE ACTVITY 
The rate of prodrug conversion can indirectly influence the absorption of prodrug or parent drug 
40-42
. 
As such esterase activity can introduce another factor of variability for the absorption of orally dosed 
ester-prodrugs. For the measurement of esterase activity, no Orlistat was added during the collection 
of the samples as it can inhibit esterase activity 
43
. The activity assay is based on conversion of a 
‘’small ’’ acetate ester, as larger esters are generally converted by specific esterases (e.g. lipases) 26. 
Figure 6 C and F show that, in contrast to lipases, esterases do not differ between fasted (270-4900 
U/ml) and fed state (430-4655 U/ml). Non-specific esterases such as carboxyl esterase are expressed in 
almost all tissues including the duodenum 
42
. Hence, concentrations are not only influenced by 
pancreatic secretions and might even be higher near the intestinal brush border.  
6 CONCLUSION 
This work has generated a comprehensive overview of human intestinal fluid composition with an 
unparalleled insight into its time-, food- and subject-dependent variability. As such, it provides a solid 
data-set for future development of biorelevant absorption profiling tools. Considering the high 
interindividual variability, the use of averages might be misleading when simulating HIF composition. 
None of the pooled samples mimicked the total average composition that was observed. Therefore, in 
addition to ‘’average’’ SIF it might be useful to generate SIF for high and low responders, as well as 
time-dependent variations, to investigate potential effects on drug dissolution, solubility and 
permeability. Incorporating the observed variations in HIF composition into physiology- and 
population-based simulation tools will be a vital step towards the improved prediction of variability in 
intestinal drug absorption. 
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8 FIGURES 
  
Figure 1: (A) A double-lumen catheter is positioned near 
the ligament of treitz. (B) Sampling protocol over time. 
Sampling was performed every 10 minutes for a period of 
1.5h in both fasted and fed state. T0 and T110 were not 
included. Between T90 and T110 was a resting period.  
(B) 
(A) 
19 
 
  
Figure 2: Overall variability in the composition of HIF aspirated as a function of time from 20 volunteers, presented 
as individual data points. Mean and median values are displayed using a solid or dashed line, respectively. The exact 
values for mean (above the solid line) and median values (above the dashed line) are displayed below their 
respective graphs, in the same unit of measurement as used in the graph.  
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Figure 3:  (A) Bile salts composition in healthy volunteers (HV). Each symbol represents the average bile acid 
composition of 1 HV. The solid line represents the mean value. The average percentages for TC, TCDC, TDC, GC, 
GCDC, and GDC are displayed below the graph. TUDC and GUDC are not included in the figure because of their 
minimal occurrence and variation; however, they complete the composition with, on average, 0.3% and 1.6%, 
respectively. (B) Examples of the bile acid composition as a function of time in 4 representative volunteers. 
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Figure 4: Time-dependent evolution of (A) pH, (B) Bile salts, (C) Phospholipids, (D) Bile acid over Phospholipid 
ratio, (E) Cholesterol, and (F) Lipid products. Data are presented as the mean of 20 volunteers (n = 20) ± 
standard error of mean. For time points at which samples could not be collected for all volunteers, n < 20 (but 
always n ≥ 17).  
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Figure 5. Composition of volunteer pools: (A) pH (B) Bile salts (C) Phospholipids (D), Cholesterol (E) Lipids/ 
Lipid degradation products. Volunteer pools were created by combining aliquots of the time-dependent 
aspirates per volunteer. Each symbol represents a volunteer. The solid line represents the mean value. 
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Figure 6: Enzymes in HIF: (A) pancreatic lipase quantities for 10 individual volunteers, (B) Phospholipase quantities for 
10 individual volunteers, (C) Total non-specific esterase activity for p-nitrophenylacetate, (D) Pancreatic lipase 
quantities over time for 3 independent volunteers, (E) Phospholipase quantities over time for 3 independent 
volunteers, (F) Esterase activity over time for 3 independent volunteers. Pancreatic and phospholipase were 
determined in the same set of volunteers. For esterase activity separate samples without Orlistat were used. 
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Table 1: Analysis of bile salts using LC-MS/MS: (A) HPLC gradient and (B) parent and product mass used for 
detection 
 
  
(A) HPLC gradient 
 
 (B) Mass  
Time Acetonitrile  
% 
Methanol 
 % 
H2O  
% 
Buffer 
 % 
  Parent  Daughter Collision 
energy 
0.0 0.0 5.0 91.0 4.0  TUDC-TCDC-TDC 498.258 124.05 52 
0.5 0.0 5.0 91.0 4.0  GUDC-GCDC-GDC 448.275 74.250 43 
1.0 13.0 48.0 35.0 4.0  TC 514.257 124.05 52 
5.0 13.0 48.0 35.0 4.0  GC 464.269 74.250 41 
7.0 19.0 48.0 29.0 4.0  UDC-CDC-DC 391.256 --- 0 
8.9 19.0 48.0 29.0 4.0  C 407.252 343.252 37 
9.0 33.0 48.0 15.0 4.0  LC 375.228 --- 37 
10.4 33.0 48.0 15.0 4.0  D4C (IS) 411.286 347.153 0 
10.5 0.0 5.0 91.0 4.0      
12.0 0.0 5.0 91.0 4.0      
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